MANORANJAN MUTHUKANAGARAJ: Open Payments
NPI 1750765244 · WASHINGTON, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$502 in 25 payments from 10 companies in 2025. Trend: 2023 $619 · 2024 $883 · 2025 $502
Food & beverage: $502
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $112 |
| Alkermes, Inc. | 3 | $75 |
| Neurocrine BioSciences, Inc. | 4 | $74 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| ABBVIE INC. | 2 | $34 |
| Janssen Pharmaceuticals, Inc | 1 | $22 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: ARISTADA, INGREZZA, TRINTELLIX, REXULTI, COBENFY, ABILIFY ASIMTUFII, VRAYLAR, UZEDY.
Industry payments across NC — which companies pay providers there.
